Get the Stockscreener App
20.59
3.32%
-0.6316
Alto Neuroscience Inc stock is traded at $20.59, with a volume of 123.48K.
It is down -3.32% in the last 24 hours and down -16.33% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$21.22
Open:
$21.13
24h Volume:
123.48K
Relative Volume:
0.40
Market Cap:
$722.23M
Revenue:
-
Net Income/Loss:
$-63.24M
P/E Ratio:
-9.1712
EPS:
-2.2449
Net Cash Flow:
$-51.79M
1W Performance:
+0.32%
1M Performance:
-16.33%
6M Performance:
+51.85%
1Y Performance:
+577.06%
1-Day Range:
$20.28
$21.27
1-Week Range:
$20.09
$21.69
52-Week Range:
$2.15
$28.44
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
20.58 | 744.69M | 0 | -63.24M | -51.79M | -2.2449 |
VRTX
Vertex Pharmaceuticals Inc
|
437.68 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.93 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.73 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.73 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.60 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-17-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Wolfe Research initiates Alto Neuroscience stock with outperform rating - Investing.com India
Alto Neuroscience Analyst Ratings and Price Targets | NYSE:ANRO - Benzinga
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
BofA Securities Adjusts Price Target on Alto Neuroscience to $33 From $35 - marketscreener.com
Wolfe Research initiates Alto Neuroscience stock with outperform rating By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained - TipRanks
Alto Neuroscience Is Maintained at Outperform by Baird - Moomoo
Alto Neuroscience Price Target Cut to $36.00/Share From $38.00 by Baird - Moomoo
Alto Neuroscience (ANRO) CEO gifts 400,000 shares to family trust - Stock Titan
Alto Neuroscience (ANRO) Vestal Point reports 6.5% ownership - Stock Titan
Point72 affiliates, Steven A. Cohen hold 3.7% of Alto Neuroscience (ANRO) - Stock Titan
[SCHEDULE 13G/A] Alto Neuroscience, Inc. Amended Passive Investment Disclosure - Stock Titan
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Radnet (RDNT) - The Globe and Mail
JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Mental health scientist wins Columbia Transformational Research Award - Stock Titan
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Business Wire
Sirenia, Alex Silverstein disclose 7.9% stake in Alto Neuroscience (ANRO) - Stock Titan
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Alto Neuroscience (NASDAQ: ANRO) director receives 10,958 stock option grant - Stock Titan
Alto Neuroscience (ANRO) director gets 10,958 options at $24.63 strike - Stock Titan
Alto Neuroscience (ANRO) director receives 10,958-share stock option grant - Stock Titan
Alto Neuroscience (ANRO) director awarded 10,958 stock options as compensation - Stock Titan
York Gwill receives 10,958 Alto Neuroscience (ANRO) stock options grant - Stock Titan
A Quick Look at Today's Ratings for Alto Neuroscience(ANRO.US), With a Forecast Between $24 to $28 - Moomoo
ANRO: ALTO-207 demonstrates robust efficacy in TRD, with late-stage trials and major catalysts ahead - TradingView
Alto Neuroscience: Runway To Fund Planned Operations Through 2029 >ANRO - Moomoo
Alto Neuroscience Shareholders Shape Governance and Equity Plans - TipRanks
Alto Neuroscience (ANRO) OKs ESPP amendment but rejects equity plan change - Stock Titan
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $35.52, Implies 44% Upside - TradingView
Alto Neuroscience, Inc. Reports Q1 2026 Financial Results and Provides Business Update - Minichart
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Alto Neuroscience Announces Strong Q1 2026 Results, Launches Pivotal Phase 2b Trial for ALTO-207 in Treatment-Resistant Depression and Secures $120M Financing 1 - Minichart
Alto Neuroscience Releases Q1 2026 Financial Results - AlphaStreet
Alto Neuroscience : Corporate Presentation - marketscreener.com
Alto Neuroscience Q1 Loss Widens - Moomoo
Earnings Flash (ANRO) Alto Neuroscience Posts Q1 Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss - marketscreener.com
[10-Q] Alto Neuroscience, Inc. Quarterly Earnings Report - Stock Titan
Alto Neuroscience reports Q1 2026 net loss of $26.2M, cash of $264.2M after $120M PIPE - TradingView
Alto Neuroscience (NYSE: ANRO) boosts cash with $120M PIPE and funds runway to 2029 - Stock Titan
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights - standard-journal.com
Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Alto Neuroscience Announces Participation in Upcoming Investor ConferencesMay 11, 2026 - BioSpace
Alto Neuroscience (NYSE:ANRO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Alto Says Investors Use Hindsight In Suit Over Drug Trial - Law360
Alto Neuroscience (ANRO) Price Target Increased by 81.11% to 19.09 - MSN
BofA Securities initiated coverage on Alto Neuroscience with a new price target - Quantisnow
BofA Securities Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $35 - Moomoo
BofA initiates Alto Neuroscience stock coverage with buy rating By Investing.com - Investing.com India
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):